ETST Earth Science Tech, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1538495 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.1%
TTM net income YoY33.6%
TTM EPS YoY-7.7%
Revenue 3-yr CAGR149.7%
Net income 3-yr CAGR144.1%
Margins
Gross margin70.2%
Operating margin—
Net margin11.0%
FCF margin2.2%
EBITDA margin—
Returns
ROE57.5%
ROA38.5%
ROIC (approx.)—
Asset turnover3.50x
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio22.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2025Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.30M | $9.03M | $9.50M | $8.39M | $9.05M | $8.76M | $8.68M | $7.35M |
| Cost of revenue | $2.24M | $2.75M | $3.22M | $1.99M | $2.33M | $2.67M | $2.14M | $2.27M |
| Gross profit | $5.06M | $6.28M | $6.27M | $6.40M | $6.72M | $6.09M | $6.54M | $5.09M |
| SG&A expense | $889,925 | $1.05M | $829,536 | $914,029 | $852,712 | $980,172 | $699,364 | $809,850 |
| Operating income | — | — | — | $1.34M | — | — | — | $226,226 |
| Interest expense | $9,565 | $16,197 | -$8 | $4,769 | $7,294 | $4,272 | $10,092 | $6,290 |
| Pretax income | $1.11M | $958,352 | $648,336 | $1.04M | $945,897 | $456,714 | $1.26M | $206,411 |
| Income tax | $276,889 | $242,655 | -$639,622 | $127,946 | — | — | $88,427 | $0 |
| Net income | $831,330 | $724,192 | $1.29M | $910,376 | $966,822 | $465,039 | $1.17M | $206,411 |
| EBITDA | — | — | — | $1.46M | — | — | — | $271,004 |
| EPS (basic) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 287.54M | 290.00M | — | 292.80M | 293.95M | 294.51M | — | 302.89M |
| Banking | ||||||||
| Net interest income | — | — | — | — | -$7,393 | -$4,272 | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.01M | $631,118 | $796,797 | $415,699 | $1.24M | $877,585 | $1.47M | $522,239 |
| Receivables | $997,670 | $845,945 | $356,054 | $306,118 | $227,189 | $341,644 | $129,064 | $164,221 |
| Inventory | $913,389 | $854,074 | $682,059 | $1.09M | $1.04M | $811,859 | $503,938 | $137,557 |
| Current assets | $4.77M | $5.09M | $3.72M | $3.03M | $3.60M | $3.08M | $3.11M | $2.01M |
| PP&E, net | $1.58M | $1.50M | $1.52M | $1.89M | $1.86M | $1.64M | $1.38M | $1.12M |
| Goodwill | $2.88M | $2.65M | $2.65M | $2.65M | $2.65M | $2.65M | $2.30M | $2.30M |
| Intangibles | $816,017 | $202,182 | $208,170 | $377,684 | $377,538 | $184,838 | $96,885 | $86,743 |
| Total assets | $10.86M | $10.37M | $8.97M | $8.09M | $8.67M | $7.78M | $7.07M | $5.71M |
| Current liabilities | $2.50M | $2.87M | $1.93M | $2.26M | $3.55M | $3.40M | $3.15M | $2.31M |
| Short-term debt | — | — | — | — | — | — | $179,488 | $30,592 |
| Long-term debt | — | — | — | — | — | — | — | $42,785 |
| Total debt | — | — | — | — | — | — | — | $73,377 |
| Total liabilities | $2.78M | $3.01M | $1.93M | $2.29M | $3.59M | $3.49M | $3.22M | $2.43M |
| Shareholders' equity | $8.05M | $7.34M | $7.01M | $5.73M | $5.00M | $4.24M | $3.85M | $3.28M |
| Net debt | — | — | — | — | — | — | — | -$448,862 |
| Shares outstanding | 286.39M | 287.59M | 291.32M | 291.61M | 292.79M | 294.30M | 294.30M | 302.66M |
| Cash flow statement | ||||||||
| Operating cash flow | $137,744 | $707,131 | $885,785 | -$126,118 | $841,820 | $339,376 | $1.99M | $500,430 |
| Capital expenditure | $652,278 | $41,417 | $155,131 | $17,473 | $351,795 | $232,220 | $296,135 | $348,435 |
| Free cash flow | -$514,534 | $665,714 | $730,654 | -$143,591 | $490,025 | $107,156 | $1.70M | $151,995 |
| Investing cash flow | $360,541 | -$480,619 | -$460,641 | -$502,948 | -$272,572 | -$668,216 | -$70,459 | -$1.70M |
| Financing cash flow | -$120,101 | -$392,191 | -$44,047 | -$190,608 | -$211,459 | -$266,803 | -$972,595 | $191,894 |
| Depreciation & amortization | $83,748 | $66,861 | -$58,355 | $121,790 | $186,398 | $34,563 | -$54,250 | $44,778 |
| Share buybacks | $120,101 | $392,191 | $5,202 | $183,184 | $202,350 | $80,674 | $415,999 | $127,096 |
Free plan shows the latest 8 periods; Pro shows all 57 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.